Followers | 898 |
Posts | 148967 |
Boards Moderated | 0 |
Alias Born | 08/13/2010 |
Friday, June 24, 2016 11:38:42 AM
Create – Discover – Deliver
Using a combinatorial rational design process and proprietary yeast strains and strain engineering technology for production of terpenoids, Amyris scientists build libraries of microorganisms that produce natural and novel compounds of pharmaceutical relevance. These compounds were previously difficult or impossible to obtain through traditional chemical synthesis.
These libraries can be generated in strains engineered to allow detection or selection of ligands with affinity to defined pharmaceutical targets. Once yeast strains with lead compounds are identified, the same combination of heterologous genes can be transferred into a yeast host optimized for terpenoid production at pilot or commercial scales.
Benefits
Nearly half of all drugs approved since 1994 are based on compounds present in natural products.
Many pharmaceutical companies have reduced or eliminated natural product drug discovery screening due to difficulties in access, complexities of natural product chemistry and purification, and challenges in supply.
There are over 30,000 known terpenoids in nature, and many terpenoid and terpene-derived molecules are biologically active signaling agents.
Amyris has developed a state-of-the-art platform for generating and screening diversity based on over a decade of experience in producing terpenoids.
Using combinatorial design, Amyris can produce more than 100,000 novel terpenoids derived from natural terpene scaffolds."
https://amyris.com/collaborations/%CE%BCpharm/
Nothing I say, post, or do should ever be considered financial advice. I may be holding a long, short or no position. I am NOT or NEVER have I been compensated to post on here or anywhere and all my posts are for entertainment purposes only.
Recent JNJ News
- Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization • Business Wire • 05/01/2024 10:30:00 AM
- Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) • Business Wire • 04/22/2024 08:30:00 PM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- US Index Futures See Gains, Oil Prices Dip • IH Market News • 04/17/2024 10:59:02 AM
- U.S. Stocks Finish Lackluster Session Narrowly Mixed • IH Market News • 04/16/2024 08:33:00 PM
- CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 02:46:00 PM
- J&J’s Q1 2024 sales rise 2.3% to $21.4 billion • IH Market News • 04/16/2024 01:52:44 PM
- Dow Looks To Snap Six-Day Losing Streak As UnitedHealth Surges • IH Market News • 04/16/2024 01:09:47 PM
- U.S. Index Futures Signal Mixed Trading, Oil Prices Dip • IH Market News • 04/16/2024 11:19:33 AM
- Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News • IH Market News • 04/16/2024 11:18:19 AM
- Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% • Business Wire • 04/16/2024 10:25:00 AM
- Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 10:20:00 AM
- U.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales Data • IH Market News • 04/15/2024 08:38:32 PM
- Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/08/2024 10:06:00 PM
- CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy • PR Newswire (US) • 04/06/2024 03:21:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc. • PR Newswire (US) • 04/05/2024 06:55:00 PM
- Apple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More Updates • IH Market News • 04/05/2024 11:38:57 AM
- Johnson & Johnson to Acquire Shockwave Medical • Business Wire • 04/05/2024 10:31:00 AM
- Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation • Business Wire • 04/04/2024 10:01:00 PM
- Johnson & Johnson to Participate in the BofA Securities Health Care Conference • Business Wire • 04/02/2024 08:30:00 PM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge • GlobeNewswire Inc. • 03/12/2024 01:15:00 PM
- Johnson & Johnson to Host Investor Conference Call on First-Quarter Results • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:58:28 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM